These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 21674534)
41. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy. Barber BJ; Andrews JG; Lu Z; West NA; Meaney FJ; Price ET; Gray A; Sheehan DW; Pandya S; Yang M; Cunniff C J Pediatr; 2013 Oct; 163(4):1080-4.e1. PubMed ID: 23866715 [TBL] [Abstract][Full Text] [Related]
42. Quantitative assessment of the T2 relaxation time of the gluteus muscles in children with Duchenne muscular dystrophy: a comparative study before and after steroid treatment. Kim HK; Laor T; Horn PS; Wong B Korean J Radiol; 2010; 11(3):304-11. PubMed ID: 20461184 [TBL] [Abstract][Full Text] [Related]
43. Pentoxifylline fails to attenuate fibrosis in dystrophic (mdx) diaphragm muscle. Gosselin LE; Williams JE Muscle Nerve; 2006 Jun; 33(6):820-3. PubMed ID: 16502423 [TBL] [Abstract][Full Text] [Related]
44. Pentoxifylline in hepatopulmonary syndrome. Kianifar HR; Khalesi M; Mahmoodi E; Afzal Aghaei M World J Gastroenterol; 2012 Sep; 18(35):4912-6. PubMed ID: 23002364 [TBL] [Abstract][Full Text] [Related]
45. Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy. Buyse GM; Goemans N; van den Hauwe M; Meier T Pediatr Pulmonol; 2013 Sep; 48(9):912-20. PubMed ID: 23129412 [TBL] [Abstract][Full Text] [Related]
46. Evidence of muscle loss delay and improvement of hyperinsulinemia and insulin resistance in Duchenne muscular dystrophy supplemented with omega-3 fatty acids: A randomized study. Rodríguez-Cruz M; Atilano-Miguel S; Barbosa-Cortés L; Bernabé-García M; Almeida-Becerril T; Cárdenas-Conejo A; Del Rocío Cruz-Guzmán O; Maldonado-Hernández J Clin Nutr; 2019 Oct; 38(5):2087-2097. PubMed ID: 30420291 [TBL] [Abstract][Full Text] [Related]
47. Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Hirtz D; Shieh PB; Straub V; Childs AM; Ciafaloni E; Butterfield RJ; Horrocks I; Spinty S; Flanigan KM; Kuntz NL; Baranello G; Roper H; Morrison L; Mah JK; Manzur AY; McDonald CM; Schara U; von der Hagen M; Barohn RJ; Campbell C; Darras BT; Finkel RS; Vita G; Hughes I; Mongini T; Pegoraro E; Wicklund M; Wilichowski E; Bryan Burnette W; Howard JF; McMillan HJ; Thangarajh M; Griggs RC Contemp Clin Trials; 2017 Jul; 58():34-39. PubMed ID: 28450193 [TBL] [Abstract][Full Text] [Related]
48. Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests. Miller NF; Alfano LN; Iammarino MA; Connolly AM; Moore-Clingenpeel M; Powers BR; Tsao CY; Waldrop MA; Flanigan KM; Mendell JR; Lowes LP Pediatr Neurol; 2020 Dec; 113():15-20. PubMed ID: 32979653 [TBL] [Abstract][Full Text] [Related]
49. Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Wagner KR; Abdel-Hamid HZ; Mah JK; Campbell C; Guglieri M; Muntoni F; Takeshima Y; McDonald CM; Kostera-Pruszczyk A; Karachunski P; Butterfield RJ; Mercuri E; Fiorillo C; Bertini ES; Tian C; Statland J; Sadosky AB; Purohit VS; Sherlock SP; Palmer JP; Binks M; Charnas L; Marraffino S; Wong BL Neuromuscul Disord; 2020 Jun; 30(6):492-502. PubMed ID: 32522498 [TBL] [Abstract][Full Text] [Related]
50. Twice-weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophy. Connolly AM; Zaidman CM; Golumbek PT; Cradock MM; Flanigan KM; Kuntz NL; Finkel RS; McDonald CM; Iannaccone ST; Anand P; Siener CA; Florence JM; Lowes LP; Alfano LN; Johnson LB; Nicorici A; Nelson LL; Mendell JR; Muscle Nerve; 2019 Jun; 59(6):650-657. PubMed ID: 30706490 [TBL] [Abstract][Full Text] [Related]
51. Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial. Buyse GM; Goemans N; van den Hauwe M; Thijs D; de Groot IJ; Schara U; Ceulemans B; Meier T; Mertens L Neuromuscul Disord; 2011 Jun; 21(6):396-405. PubMed ID: 21435876 [TBL] [Abstract][Full Text] [Related]
52. Recombinant human insulin-like growth factor-1 therapy for 6 months improves growth but not motor function in boys with Duchenne muscular dystrophy. Rutter MM; Wong BL; Collins JJ; Sawnani H; Taylor MD; Horn PS; Backeljauw PF Muscle Nerve; 2020 May; 61(5):623-631. PubMed ID: 32108355 [TBL] [Abstract][Full Text] [Related]
53. Development of a New Self-Reporting Instrument Measuring Benefits and Side Effects of Corticosteroids in Duchenne Muscular Dystrophy: Report from a Pilot Study. Hendriksen RGF; Lionarons JM; Hendriksen JGM; Vles JSH; McAdam LC; Biggar WD J Neuromuscul Dis; 2017; 4(3):217-236. PubMed ID: 28800336 [TBL] [Abstract][Full Text] [Related]
54. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Van Wagner LB; Koppe SW; Brunt EM; Gottstein J; Gardikiotes K; Green RM; Rinella ME Ann Hepatol; 2011; 10(3):277-86. PubMed ID: 21677329 [TBL] [Abstract][Full Text] [Related]
55. Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study. Goemans NM; Tulinius M; van den Hauwe M; Kroksmark AK; Buyse G; Wilson RJ; van Deutekom JC; de Kimpe SJ; Lourbakos A; Campion G PLoS One; 2016; 11(9):e0161955. PubMed ID: 27588424 [TBL] [Abstract][Full Text] [Related]
56. Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial. Kirschner J; Schessl J; Schara U; Reitter B; Stettner GM; Hobbiebrunken E; Wilichowski E; Bernert G; Weiss S; Stehling F; Wiegand G; Müller-Felber W; Thiele S; Grieben U; von der Hagen M; Lütschg J; Schmoor C; Ihorst G; Korinthenberg R Lancet Neurol; 2010 Nov; 9(11):1053-9. PubMed ID: 20801085 [TBL] [Abstract][Full Text] [Related]
57. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease. Safarinejad MR; Asgari MA; Hosseini SY; Dadkhah F BJU Int; 2010 Jul; 106(2):240-8. PubMed ID: 19863517 [TBL] [Abstract][Full Text] [Related]
58. Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study. Mercuri E; Muntoni F; Osorio AN; Tulinius M; Buccella F; Morgenroth LP; Gordish-Dressman H; Jiang J; Trifillis P; Zhu J; Kristensen A; Santos CL; Henricson EK; McDonald CM; Desguerre I; ; J Comp Eff Res; 2020 Apr; 9(5):341-360. PubMed ID: 31997646 [No Abstract] [Full Text] [Related]
59. Improved Muscle Function in Duchenne Muscular Dystrophy through L-Arginine and Metformin: An Investigator-Initiated, Open-Label, Single-Center, Proof-Of-Concept-Study. Hafner P; Bonati U; Erne B; Schmid M; Rubino D; Pohlman U; Peters T; Rutz E; Frank S; Neuhaus C; Deuster S; Gloor M; Bieri O; Fischmann A; Sinnreich M; Gueven N; Fischer D PLoS One; 2016; 11(1):e0147634. PubMed ID: 26799743 [TBL] [Abstract][Full Text] [Related]
60. Potential therapeutic impact of omega-3 long chain-polyunsaturated fatty acids on inflammation markers in Duchenne muscular dystrophy: A double-blind, controlled randomized trial. Rodríguez-Cruz M; Cruz-Guzmán ODR; Almeida-Becerril T; Solís-Serna AD; Atilano-Miguel S; Sánchez-González JR; Barbosa-Cortés L; Ruíz-Cruz ED; Huicochea JC; Cárdenas-Conejo A; Escobar-Cedillo RE; Yam-Ontiveros CA; Ricárdez-Marcial EF Clin Nutr; 2018 Dec; 37(6 Pt A):1840-1851. PubMed ID: 28987470 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]